An early review found self-reported relief from menopausal brain fog with ADHD drugs, but no clear cognitive test benefit. Here is the practical meaning.
On October 8, 2026, The Menopause Society reported preliminary findings from a review of lisdexamfetamine and atomoxetine for menopause-related brain fog. If you value independent travel and active days outdoors, the question is relevant: might treatment make the mental side of everyday life feel more manageable?
The review was presented as a poster at the Society’s 2026 annual meeting. It examined ADHD medications and cognitive or ADHD-related symptoms during the menopause transition. Its central finding concerns women’s reported experience of thinking and managing tasks, rather than an established improvement in cognitive performance.
That distinction matters when your goal is capability. Feeling less mentally burdened is meaningful, but it is not automatically evidence of better attention or memory under testing.
According to The Menopause Society, the review authors found preliminary improvement in self-reported executive-function symptoms with lisdexamfetamine and atomoxetine. Lisdexamfetamine is a stimulant. Atomoxetine is a non-stimulant.
In everyday terms, the self-report finding asks whether participants experienced fewer difficulties managing the mental demands of daily life. It concerns how thinking feels to the person doing it. That is a different question from how accurately someone performs a defined cognitive task.
The review’s objective measures included working memory and sustained attention. These address abilities such as holding information in mind and maintaining attention during a task. The authors reported little or no significant benefit on those measures, according to The Menopause Society and MedPage Today.
Neither kind of measurement should be substituted for the other. A questionnaire can capture a change that matters to someone’s day. A cognitive test examines performance under particular conditions. The useful reading is to keep the two results separate rather than turn a subjective improvement into a broader claim about sharper thinking.
For an active adult, this is more than a technical distinction. Finding daily demands easier to manage and demonstrating better performance are both relevant goals. They simply require different evidence.
This question also belongs within the wider conversation about midlife brain health, rather than being treated as an isolated opportunity for a pharmaceutical boost.
MedPage Today reports that the review included five studies. Three were crossover randomized controlled trials involving 60 participants in total. The other two were cross-sectional studies involving 6,048 participants in Iceland and the U.K.
The distinction between these groups is important. The trials included both self-reported symptoms and objective cognitive measures. The cross-sectional studies used the Adult ADHD Self-Report Scale and validated menopause scales, according to MedPage Today.
The larger participant count therefore should not be mistaken for a large medication trial. The studies contributed different kinds of information. Adding their populations together would obscure how much evidence actually came from randomized treatment comparisons.
The clearest numerical findings concerned the Brown Attention Deficit Disorder Scale, known as BADDS. MedPage Today describes this as a self-report measure in which lower scores indicate less reported executive dysfunction.
For lisdexamfetamine, scores fell from 35.7 to 21.2, compared with 29.8 with placebo. For atomoxetine, scores fell from a baseline of 38.6 to 25.5, compared with 30.1 with placebo. These are the reported questionnaire results from the trials.
The placebo comparisons matter because they provide context for interpreting the changes. Yet the scale itself still determines what those numbers describe: participants’ reported difficulties. A lower BADDS score is not a measurement of faster route-finding or greater mental stamina during a demanding day outdoors.
The finding worth retaining is therefore specific. The review identified a signal of improvement in perceived executive-function symptoms. It did not establish a general-purpose enhancement of cognition.
The Menopause Society said larger studies are needed to establish safety and effectiveness before these medications can be recommended for menopausal brain fog. This was an early review presented at a meeting, not a clinical guideline endorsing routine prescribing for this purpose.
Healthline reports that ADHD medications are not FDA-approved specifically for menopause-related brain fog. Use for that purpose would be off-label. That status is relevant to a clinical discussion, rather than a reason to assume that a familiar medication has already been established for a different concern.
Healthline also notes potential cardiovascular side effects from ADHD medications. It identifies misuse and dependence as concerns with lisdexamfetamine. These are general medication cautions, not estimates of a particular risk level established by this review in menopausal patients.
Taken together, these boundaries explain why the result calls for further assessment rather than a new default treatment. The research question is promising enough to pursue. It is not yet a settled prescribing answer.
The review provides no evidence that either medication improves travel recovery, altitude adjustment or sustained energy during skiing and hiking. Those outcomes should not be attached to a finding about self-reported executive-function symptoms.
For travel, the practical value of the news is a more precise way to discuss what feels difficult. Keeping track of an itinerary is a different concern from recovering after a flight. Following a guide’s briefing is a different concern from maintaining physical energy throughout an excursion.
Those distinctions help keep the conversation focused on the actual problem. If managing plans has become harder, describe that difficulty rather than asking generally for more energy. If the concern is losing track during instructions, describe that instead of assuming that every lapse has the same explanation.
These are examples for a clinical conversation, not diagnostic tests or outcomes demonstrated by the review. They make the question more concrete without turning an upcoming journey into a medication experiment.
The same approach fits sport. For a skier or hiker, capability includes understanding plans as well as completing the physical day. This review makes the experience of mental difficulty worth discussing on its own terms. It does not require that concern to be translated into a claim about athletic performance.
There is also no need to make a medication decision simply because a demanding trip is approaching. The defensible action supported by this research is to discuss symptoms with a qualified clinician. Borrowing someone else’s prescription is not an appropriate response to the findings.
Lead author Jennifer Tat pointed toward ADHD screening as a way to help women receive appropriate care, according to The Menopause Society. That is a different proposition from treating menopause-related brain fog as sufficient reason to prescribe an ADHD medication.
AARP reported Tat’s view that these findings do not mean ADHD drugs should be prescribed in an OB-GYN setting. Instead, a positive screen could lead to referral for a structured psychiatric assessment. The proposed next step is better evaluation rather than an automatic prescription.
For the reader, the most useful preparation is to make the difficulty concrete. Describe what feels harder and how it affects activities you want to keep doing. Keep the focus on the experience that prompted concern rather than arriving with a medication already selected.
A screening result belongs within that assessment process. It should not be treated as a personal diagnosis made from a headline or a questionnaire taken in isolation. Tat’s suggested referral pathway preserves the distinction between identifying symptoms and deciding what they mean.
This is an appropriately practical response to an early finding. It takes women’s reported difficulties seriously while leaving individual medication decisions with qualified care. It also keeps the goal where it belongs: a more manageable daily life rather than a pursuit of enhancement for its own sake.
WealthAtPlay’s broader guide to protecting mental performance places that goal within the larger aim of staying sharp and independent. A single medication finding is one part of that conversation, not a replacement for it.
Treat menopause-related brain fog as a reason for a focused clinical conversation about daily capability, not a reason to add ADHD medication to your travel or training routine.
Stay connected for research and practical guidance on longevity, strength, recovery, energy and active living. New ideas to help you stay capable, curious and ready for more.
Explore practical guidance on strength, recovery, energy, travel and longevity for a life that stays active.
explore the Blog
